Abstract 1905P
Background
Tertiary lymphoid structures (TLS) are organized aggregates of immune cells that form postnatally in non-lymphoid tissues and arise under physiological conditions. However, the clinical and immunological implications of heterogeneous subpopulations of TLS in clear cell renal cell carcinoma (ccRCC) remain to be elucidated.
Methods
H&E, immunohistochemistry and 12-marker multispectral fluorescent were used to evaluate the spatial location and maturation status of TLS with TME cell-infiltrating characterizations. We comprehensively assessed the prognostic value of TLS heterogeneity in 395 patients with ccRCC from two independent cohorts using log-rank tests, Cox hazards models, and scoring nomograms. Associations between TLS heterogeneity and immunologic activity of TME were assessed using quantified lymphocytes infiltration fraction.
Results
By pathological review, TLS were identified in 34.2% of the ccRCC samples. For ccRCC patients, the presence of intratumoral TLS markedly correlated with both superior progression-free survival (PFS) and overall survival (OS), while the peritumoral TLS exerted the opposite predictive trend of clinical outcomes. Multivariate Cox analysis revealed that the presence of intratumoral TLS was prominently correlated with better outcomes. Additionally, the novel nomograms incorporating the presence of intratumoral TLS prominently predicted the probability of 8-year PFS and OS of ccRCC (AUC >0.80). Moreover, a higher proportion of early TLS was found in peritumoral TLS (P=0.016), while intratumoral TLS were mainly composed of secondary follicle-like TLS (P=0.004). Interestingly, in ccRCC samples with the presence of peritumoral TLS enriched with primary follicle-like TLS, the proportion of PD-L1+ tumor-associated macrophages and Treg infiltration in the stroma were prominently increased, showing a typical suppressive tumor immune microenvironment.
Conclusions
In conclusion, this study revealed the predictive value of TLS heterogeneity on the progression and immunological responses of ccRCC for the first time. The intratumoral TLS could be used to assess both the prognostic patterns and the unique TME characteristics of each patient.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1706P - Time to full approval of novel anticancer medicines granted accelerated approval and implications for reform of the accelerated approval pathway
Presenter: Thomas Hwang
Session: Poster session 23
1707P - Cancer drug prices in the US: Efficacy, innovation, clinical trial evidence, and epidemiology
Presenter: Christoph Michaeli
Session: Poster session 23
1708P - The registration pathways in China for globally developed novel anticancer drugs
Presenter: Da-wei Wu
Session: Poster session 23
1709P - Influence of censoring on conclusions of FDA-approved cancer drugs using the modified time to treatment failure
Presenter: Jonathan Ofer
Session: Poster session 23
1710P - Protocol waivers and consequences on treatment safety and efficacy in the Drug Rediscovery Protocol (DRUP)
Presenter: Laurien Zeverijn
Session: Poster session 23
1711P - The DRUP-like clinical trials family: A distributed European trial network for equitable access to precision medicine
Presenter: Hans Gelderblom
Session: Poster session 23
1712P - Implementation of a molecular pre-screening program (MPP) in a network of public cancer centres for phase I clinical trial (Ph1-CT) candidates: The PREICO program
Presenter: Juan José Soto Castillo
Session: Poster session 23
1713P - Non-inferiority oncology clinical trials in major journals: Purposes, methods and results
Presenter: Rafael Barreto
Session: Poster session 23
1714P - Geographical disparities in access to cancer clinical trials in Korea
Presenter: Sokbom Kang
Session: Poster session 23
1715P - Analysis of the adequacy of control arms in oncology randomized clinical trials published between 2017 and 2021: A meta-research study
Presenter: Alessandro Rossi
Session: Poster session 23